News & Views

  • Respiratory Diseases Portfolio Acquired for Development
    John Ford

Respiratory Diseases Portfolio Acquired for Development

Oct 15 2020 Read 247 Times

Biopharmaceutical company Enterprise Therapeutics, a developer of therapies for respiratory disease, has announced that its TMEM16A potentiator portfolio has been fully acquired by Roche and will be developed by Genentech, a member of the Roche Group. The portfolio includes ETD002 which recently entered Phase 1 trials.

Enterprise’s shareholders received an upfront payment of £75 million and are eligible to receive additional contingent payments, to be made based on the achievement of certain predetermined milestones.

The TMEM16A portfolio is focused toward treating all people with cystic fibrosis (CF), with potential to benefit people with other severe respiratory diseases characterised by excessive mucus congestion.

Dr John Ford, CEO, Enterprise Therapeutics, said: “Roche and Genentech have a proven track record of bringing new medicines to people with respiratory diseases, and have recognised the opportunity that our TMEM16A potentiator portfolio presents. I am very proud of the team at Enterprise for identifying and developing this innovative approach to treat patients, with ETD002 the first of our compounds to reach clinical stage. TMEM16A potentiation has the potential to significantly increase the quality of life for people living with cystic fibrosis, for many of whom existing therapies are not effective.”

Dr James Sabry, MD, PhD, Global Head of Pharma Partnering, Roche, commented: “We are excited to add Enterprise’s TMEM16A potentiator program to our existing respiratory portfolio. We have deep capabilities in this area and look forward to a robust program focused on helping cystic fibrosis patients and patients suffering from other muco-obstructive disorders as quickly as possible.”

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment





Digital Edition

Measurement Analysis China 2021 Buyers Guide

November 2020

The following Buyers’ Guide has been produced by International Labmate Ltd. International Labmate have been publishing magazines for over 46 years. We now publish 9 laboratory, environmental and...

View all digital editions

Events

Expomed Eurasia - NEW DATES

Nov 05 2020 Istanbul, Turkey

Pharma Asia - NEW DATES

Nov 10 2020 Karachi, Pakistan

JASIS 2020

Nov 11 2020 Chiba City, Japan

International Solid Waste Management Summit

Nov 12 2020 Shanghai, China

SETAC North America

Nov 15 2020 Virtual event

View all events